Skip to main content
Nuopu Regenerative Medicine receives Class III medical device registration for AM-extruded bone filler
Product
2 min read

Nuopu Regenerative Medicine receives Class III medical device registration for AM-extruded bone filler

Originally reported by bydrug.pharmcube.com

Nuopu Regenerative Medicine, a BioBAY-based biotechnology firm, has officially obtained a Class III medical device registration certificate from China's National Medical Products Administration (NMPA). The certification covers its proprietary additive manufacturing (AM) bone filler designed specifically for oral applications, such as alveolar bone defect repair. This product is the first in China to utilize a polymer composite extrusion printing process to create a single-piece, biodegradable, and porous biomimetic bone regeneration scaffold. The manufacturing process relies on the company's OPUS bio-3D printing platform, which enables precise spatial arrangement of regenerative materials to facilitate optimal tissue ingrowth.

This regulatory milestone addresses critical limitations in current dental and maxillofacial reconstructive procedures, including the secondary trauma associated with autologous bone harvesting and the immunological risks of allogeneic bone grafts. By utilizing extrusion-based AM, Nuopu provides a solution that offers superior structural support and osteoconductive guidance compared to traditional bone powders. The ability to manufacture personalized, digitally-defined scaffolds allows for better anatomical fit and more predictable clinical outcomes in complex defect sites. As the medical AM sector shifts from simple anatomical models to functional, bio-resorbable implants, Nuopu's integration of material science with extrusion-based precision positioning places it in a specialized niche of the regenerative medicine value chain.

For Nuopu, the immediate priority is the commercial scale-up of the OPUS platform to meet clinical demand while maintaining the strict quality controls required for Class III devices. The company must now transition from R&D success to establishing a robust supply chain for its specialized polymer composites. Clinicians should evaluate the product's degradation rates and mechanical stability in load-bearing oral environments as it enters the market.

Topics

Nuopu Regenerative Medicinebio-3D printingextrusion printingbone fillerClass III medical devicealveolar bone repairChinabiomimetic scaffold

How This Connects

6 related events
  1. This article

    Nuopu Regenerative Medicine receives Class III medical device registration for AM-extruded bone filler

  2. Same pattern

    Cyfuse partners with Keio University and Fujita Health University for 3D bioprinted knee joint clinical trials

  3. Same pattern

    Beijing Institute of Technology researchers Dr.

  4. Same pattern

    Aspect Biosystems secures $280M to scale bioprinted tissue therapy production in Canada.

  5. Same pattern

    Georgetown University researchers are developing a 3D printable bone graft scaffold utilizing pectin, a polysaccharide derived from plant cell walls, as a sustainable and biocompatible material.

  6. Same pattern

    Cyfuse and NSK announce the development of a new bio-3D printer designed for the commercial production of regenerative medicine and 3D cell products.

  7. Same pattern

    EPFL researchers developed a room-temperature 3D printing process using enzyme-driven mineralization to create bone scaffolds that become load-bearing within 7 days.